200 related articles for article (PubMed ID: 26068553)
1. Successes and setbacks of early investigational drugs for melanoma.
Orloff M; Valsecchi ME; Sato T
Expert Opin Investig Drugs; 2015; 24(8):993-7. PubMed ID: 26068553
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy in the treatment of advanced or metastatic melanoma: nivolumab from phase I studies to approvement by European Medicines Agency].
Queirolo P; Tanda ET
Recenti Prog Med; 2015 Dec; 106(12):608-17. PubMed ID: 26780070
[TBL] [Abstract][Full Text] [Related]
3. Spotlight on pembrolizumab in the treatment of advanced melanoma.
Rajakulendran T; Adam DN
Drug Des Devel Ther; 2015; 9():2883-6. PubMed ID: 26082618
[TBL] [Abstract][Full Text] [Related]
4. New therapeutical strategies in the treatment of metastatic disease.
Julia F; Thomas L; Dalle S
Dermatol Ther; 2012; 25(5):452-7. PubMed ID: 23046024
[TBL] [Abstract][Full Text] [Related]
5. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
Zhu Z; Liu W; Gotlieb V
Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
[TBL] [Abstract][Full Text] [Related]
6. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma.
Sullivan RJ; Flaherty KT
Clin Cancer Res; 2015 Jul; 21(13):2892-7. PubMed ID: 25931451
[TBL] [Abstract][Full Text] [Related]
8. New targeted therapies in melanoma.
Kudchadkar RR; Gonzalez R; Lewis K
Cancer Control; 2013 Oct; 20(4):282-8. PubMed ID: 24077404
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab approved for metastatic melanoma.
Traynor K
Am J Health Syst Pharm; 2011 May; 68(9):768. PubMed ID: 21515855
[No Abstract] [Full Text] [Related]
10. Pharmacotherapy of metastatic melanoma: emerging trends and opportunities for a cure.
Pretto F; Neri D
Pharmacol Ther; 2013 Sep; 139(3):405-11. PubMed ID: 23711792
[TBL] [Abstract][Full Text] [Related]
11. [What’s new in dermato-oncology?].
Quéreux G
Ann Dermatol Venereol; 2013 Nov; 140 Suppl 3():S283-92. PubMed ID: 24365500
[TBL] [Abstract][Full Text] [Related]
12. New drugs in melanoma: it's a whole new world.
Eggermont AM; Robert C
Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280
[TBL] [Abstract][Full Text] [Related]
13. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
14. Therapy for metastatic melanoma: the past, present, and future.
Finn L; Markovic SN; Joseph RW
BMC Med; 2012 Mar; 10():23. PubMed ID: 22385436
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
Eggermont AM; Maio M; Robert C
Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma.
Hughes T; Klairmont M; Sharfman WH; Kaufman HL
Cancer Biol Ther; 2021 Dec; 22(10-12):513-526. PubMed ID: 26418961
[TBL] [Abstract][Full Text] [Related]
17. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma.
Basile D; Lisanti C; Pizzichetta MA; Baldo P; Fornasier G; Lo Re F; Corona G; Puglisi F
Recent Pat Anticancer Drug Discov; 2019; 14(3):203-225. PubMed ID: 31362664
[TBL] [Abstract][Full Text] [Related]
18. Targeting MAPK pathway in melanoma therapy.
Cheng Y; Zhang G; Li G
Cancer Metastasis Rev; 2013 Dec; 32(3-4):567-84. PubMed ID: 23584575
[TBL] [Abstract][Full Text] [Related]
19. GSK drug combination approved for advanced melanoma.
Inman S
Am J Manag Care; 2014 Feb; 20(2 Spec No.):E10. PubMed ID: 25764581
[No Abstract] [Full Text] [Related]
20. Advanced stage melanoma therapies: Detailing the present and exploring the future.
Luther C; Swami U; Zhang J; Milhem M; Zakharia Y
Crit Rev Oncol Hematol; 2019 Jan; 133():99-111. PubMed ID: 30661664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
